When the body does not collaborate: pharmacological treatment of obesity
https://doi.org/10.15829/1560-4071-2013-4-70-73
Abstract
The paper presents the modern evidence on pharmacological treatment of patients with obesity and comorbidities, who try to modify their lifestyle, but are unsuccessful due to metabolic disturbances. The main and recently discovered additional effects of orlistat are discussed.
About the Author
E. O. Taratukhin
N. I. Pirogov Russian National Medical Research University, Moscow, Russia
Russian Federation
Russian Federation
References
1. Asai M, Joachim M, Shen Y. Loss of function of the melanocortin 2 receptor accessory
2. protein 2 is associated with mammalian obesity. Science, 2013; 34: 275–8.
3. Cawley J (ed.) The Oxford Handbook of the Social Science of Obesity. Oxford University Press, 2011, 912p.
4. Martin-Gronert MS, Ozanne SE. Early life programming of obesity. Med Wieku Rozwoj,
5. ; 17 (1): 17–2.
6. Hebert JR, Allison DB, Archer E et al. Scientific decision making, policy decisions and the obesity pandemic. Mayo Clin Proc, 2013; 88 (6): 593–604.
7. Harris CM, Rios R, Landis R et al. Receptivity to weight management interventions among hospitalized obese patients: an untapped opportunity. South Med J, 2013; 106 (6):
8. –42.
9. The Internet Drug Indx: RxList. URL: http://www.rxlist.com/xenical-drug.htm – обра-
10. щение 27.08.2013.
11. Siebenhofer A, Jeitler K, Horvath K et al. Long-term effects of weight-reducing
12. drugs in hypertensive patients. Cochrane Database Syst Rev, 2013; 28:3 DOI:
13. 1002/14651858.
14. Blackett P, Tryggestad J, Krishnan S et al. Lipoprotein abnormalities in compound
15. heterozygous lipoprotein lipase deficiency after treatment with a low fat diet and
16. orlistat. J Clin Lipidol, 2013; 7 (2): 132–9.
17. Svacina S. Treatment of obese diabetics. Adv Exp Med Biol, 2012; 771: 459–64.
18. Kujawa A, Szponar J, Szponar E et al. The harmfulness of drugs and slimming substances – a toxicologist’s point of view. Przegl Lek, 2012; 69 (8): 548–51.
19. Carter R, Mouralidarane A, Ray S et al. Recent advancements in drug treatment of obesity. Clin Med, 2012; 12 (5): 456–60.
20. Tirado-Velez JM, Joumady I, Saez-Benito A et al. Inhibition of fatty acid metabolism reduces human myeloma cells proliferation. PLoS One, 2012; 7 (9) – DOI: 10.1371/0046484.
21. Seguin F, Carvalho MA, Bastos DC et al. The fatty acid syntase inhibitor orlistat reduces experimental metastases and angiogenesis in B16-F10 melanomas. Br J Cancer, 2012; 107: 977–87.
22. Chukhin E, Takala P, Hakko H et al. In a randomized placebo-controlled add-on study
23. orlistat significantly reduced clozapine-induced constipation. In Clin Psychopharmacol,
24. ; 28 (2): 67–70.
25. Das C, Mendez G, Jagasia S et al. Second-generation antipsychotic use in schizophrenia and associated weight gain: a critical review and meta-analysis of behavioral and pharmacologic treatments. Ann Clin Psychiatry, 2012; 24 (3): 225–39.
26. Morris M, Lane P, Lee K et al. An integrated analisys of liver safety data from orlistat clinical trials. Obes Facts, 2012; 5 (4): 485–94.
27. Yen M, Ewald MB. Toxicity of weight loss agents. J Med Toxicol, 2012; 8 (2): 145–52.
28. Chilton M, Dunkley A, Carter P et al. The effect of anti-obesity drugs on waist circumference: a mixed treatment. Diabetes Obes Metab, 2013; DOI: 10.1111/dom.12198.
Review
For citations:
Taratukhin E.O. When the body does not collaborate: pharmacological treatment of obesity. Russian Journal of Cardiology. 2013;(4):70-73. (In Russ.) https://doi.org/10.15829/1560-4071-2013-4-70-73
Views:
811
Email this article 